Physician profile
Lisa E Flaum
NPI 1740261262
$234,035.94
in general payments reported to CMS, 2019-2025
10 companies · $39K in 2025
The $39K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $6,858 · 2021: $18K · 2022: $33K · 2023: $27K · 2024: $60K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Consulting Fee: $13K · Food and Beverage: $3,411 · Travel and Lodging: $3,020 · Long Term Medical Supply Or Device Loan: $2,250 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,490.00 |
| Consulting Fee | $12,705.00 |
| Food and Beverage | $3,411.10 |
| Travel and Lodging | $3,019.67 |
| Long Term Medical Supply Or Device Loan | $2,249.91 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $166,129.84 | 2019-2025 | Enhertu, Lynparza, Datroway |
| Novartis Pharmaceuticals Corporation | $35,890.93 | 2019-2025 | Kisqali |
| Seagen INC. | $19,321.59 | 2020-2022 | |
| Daiichi Sankyo INC. | $9,163.58 | 2022-2025 | Enhertu |
| Eisai INC. | $2,774.74 | 2019 | |
| Gilead Sciences, INC. | $249.71 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $230.18 | 2024-2025 | Keytruda, Lynparza |
| Pfizer INC. | $142.35 | 2023-2024 | |
| Puma Biotechnology, INC. | $118.74 | 2019 | |
| Celgene Corporation | $14.28 | 2024 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Flaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.